180 related articles for article (PubMed ID: 22726550)
1. Proteasome inhibition for antibody-mediated allograft rejection.
Sadaka B; Alloway RR; Shields AR; Schmidt NM; Woodle ES
Semin Hematol; 2012 Jul; 49(3):263-9. PubMed ID: 22726550
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
Woodle ES; Alloway RR; Girnita A
Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition for antibody-mediated rejection.
Everly JJ; Walsh RC; Alloway RR; Woodle ES
Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
[TBL] [Abstract][Full Text] [Related]
4. Clinical and investigational use of proteasome inhibitors for transplant rejection.
Sadaka B; Alloway RR; Woodle ES
Expert Opin Investig Drugs; 2011 Nov; 20(11):1535-42. PubMed ID: 21916809
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitor therapy for antibody-mediated rejection.
Woodle ES; Walsh RC; Alloway RR; Girnita A; Brailey P
Pediatr Transplant; 2011 Sep; 15(6):548-56. PubMed ID: 21884344
[TBL] [Abstract][Full Text] [Related]
6. Management of antibody-mediated rejection in transplantation.
Sadaka B; Alloway RR; Woodle ES
Surg Clin North Am; 2013 Dec; 93(6):1451-66. PubMed ID: 24206861
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
Liang Y; Liu H
Curr Pharm Des; 2013; 19(18):3299-304. PubMed ID: 23151133
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
11. Dissecting bortezomib: development, application, adverse effects and future direction.
Cao B; Li J; Mao X
Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
Trials; 2014 Apr; 15():107. PubMed ID: 24708575
[TBL] [Abstract][Full Text] [Related]
13. Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient.
Claes DJ; Yin H; Goebel J
Pediatr Transplant; 2014 Jun; 18(4):E100-5. PubMed ID: 24725066
[TBL] [Abstract][Full Text] [Related]
14. Review of bortezomib treatment of antibody-mediated rejection in renal transplantation.
Ejaz NS; Alloway RR; Halleck F; Dürr M; Budde K; Woodle ES
Antioxid Redox Signal; 2014 Dec; 21(17):2401-18. PubMed ID: 24635140
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.
Moran E; Carbone F; Augusti V; Patrone F; Ballestrero A; Nencioni A
Semin Hematol; 2012 Jul; 49(3):270-6. PubMed ID: 22726551
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
17. Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice.
Redfield RR; Lou Y; Rodriguez E; Rostami S; Parsons RF; Noorchashm H; Naji A; Abt PL
Transpl Immunol; 2013 Dec; 29(1-4):11-6. PubMed ID: 24103731
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.
Guthoff M; Schmid-Horch B; Weisel KC; Häring HU; Königsrainer A; Heyne N
Transpl Immunol; 2012 Jun; 26(4):171-5. PubMed ID: 22326708
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition reduces donor-specific antibody levels.
Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Brown E; Tevar A; Woodle ES
Transplant Proc; 2009; 41(1):105-7. PubMed ID: 19249489
[TBL] [Abstract][Full Text] [Related]
20. [Development and clinical application of novel proteasome inhibitors].
Iida S
Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
[No Abstract] [Full Text] [Related]
[Next] [New Search]
